---
title: "诺和诺德基金会：计划让雷本·索伦森担任诺和诺德董事长，任期为两到三年的临时期限。"
description: "诺和诺德基金会：计划让雷本·索伦森担任诺和诺德董事长，任期为两到三年的临时期限。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262053484.md"
published_at: "2025-10-21T12:15:32.000Z"
---

# 诺和诺德基金会：计划让雷本·索伦森担任诺和诺德董事长，任期为两到三年的临时期限。

诺和诺德基金会：计划让雷本·索伦森担任诺和诺德董事长，任期为两到三年的临时期限。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/zh-CN/news/276442777.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-CN/news/276447697.md) |
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/zh-CN/news/276056741.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/zh-CN/news/276440991.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/zh-CN/news/276280378.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
